Skip Navigation



eCAM Advance Access published online on February 7, 2006
eCAM, doi:10.1093/ecam/nek022
This Article
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
3/1/25    most recent
nek022v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Vojdani, A.
Right arrow Articles by Erde, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vojdani, A.
Right arrow Articles by Erde, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press. All rights reserved.
Received December 27, 2005
Accepted January 7, 2006

Review

Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: The Ultimate Antagonist (I)

Aristo Vojdani 1 and Jonathan Erde 1 *

1 Immunosciences Laboratory, Inc., 8693 Wilshire Boulevard, Suite 200, Beverly Hills, CA 90211, USA

* To whom correspondence should be addressed.
Jonathan Erde, E-mail: jerde{at}lion.lmu.edu


  Abstract

Over the past decade, great interest has been given to regulatory T (Treg) cells. A vast body of evidence has shown the existence and highlighted the importance of Treg cells in the active suppression of immune system responses. This form of immunoregulation is the dominant means utilized by the immune system to reach a harmony between reciprocal response processes in order to ensure adequate host defense with minimal host detriment. Therapeutically targeting Treg cells is a direct and powerful means to manipulate the immune system to achieve beneficial effects on various disease pathologies, including allergy, autoimmunity and cancer, as well as the facilitation of organ transplantation. This powerful target for immunoregulation is of much concern to practitioners and researchers of complementary and alternative medicine because it allows a great deal of control and certainty in dealing with the prevalence of debilitating immune system-related disorders for which there has been little remedy outside of Western Medicine.

Keywords: immune system modulation; regulatory T cells; Treg.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
P. Correale, P. Tagliaferri, A. Fioravanti, M. T. Del Vecchio, C. Remondo, F. Montagnani, M. S. Rotundo, C. Ginanneschi, I. Martellucci, E. Francini, et al.
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)
Clin. Cancer Res., July 1, 2008; 14(13): 4192 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
N. Yamaguchi, T. Takahashi, M. Sakuma, T. Sugita, K. Uchikawa, S. Sakaihara, T. Kanda, M. Arai, and K. Kawakita
Acupuncture Regulates Leukocyte Subpopulations in Human Peripheral Blood
Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 447 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
P. Bellavite, R. Ortolani, F. Pontarollo, V. Piasere, G. Benato, and A. Conforti
Immunology and Homeopathy. 4. Clinical Studies--Part 1
Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 293 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
A. Vojdani and J. Erde
Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Tumor Immunity, Autoimmunity and Alloreactive Immunity (III)
Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 309 - 316.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.